SRT Therapeutics is a San Diego-based biotech company established in 2024 by the founders of Prometheus Biosciences, Steph Targan, MD (Cedars Sinai), Janine Bilsborough, Ph.D. (Cedars Sinai), the scientific team that discovered Tulisokibart (MK7240) and the role of TL1A in IBD and Scott Glenn and Lauren Otsuki, the drug development team that took Tulisokibart (MK7240) from academia into the clinic. Building on the demonstrated success of the precision medicine approach in IBD with Tulisokibart, SRT Therapeutics will expand this approach by targeting key pathways that not only modulate inflammatory pathways, but also promote tissue healing in IBD. This strategy will move SRT Therapeutics beyond the current empirical treatment model to realize the goal of enhancing both outcomes and the quality of care for our patients.
Company Details
- Employees
- 14
- Founded
- -
- Address
- San Diego , California , Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://srt-tx.com/
- HQ
- San Diego , California
Srt Therapeutics Inc. Questions
Srt Therapeutics Inc.'s website is https://srt-tx.com/
Srt Therapeutics Inc.'s LinkedIn profile is https://www.linkedin.com/company/srt-therapeutics-inc
Srt Therapeutics Inc. has
14 employees.
View email and phone details for 14
employees at Srt Therapeutics Inc..
Srt Therapeutics Inc.'s industry is
Biotechnology Research
Srt Therapeutics Inc.'s top competitors are
Avidity Biosciences, Inc.,
Light Horse Therapeutics,
Seawolf Therapeutics, Inc.,
Copoly.ai,
Aizen Therapeutics,
Poseida Therapeutics, Inc.,
Mirador Therapeutics,
Emles Bioventures,
Fate Therapeutics Inc.,
Turnstone Biologics.
Srt Therapeutics Inc.'s categories are Biotechnology Research
Srt Therapeutics Inc.'s founding year is 2024
